Date of report 13 May 2019
Reported case interaction between
Dolutegravir and Mineral supplements

FLS Science

Drugs suspected to be involved in the DDI

Victim
Dolutegravir
Daily Dose
50 (mg)
Dose adjustment performed
No
Administration Route
Oral
Start date
Dec. 2, 2015
End date
Ongoing
Perpetrator
Mineral supplements
Daily Dose
Unknown
Dose adjustment performed
No
Administration Route
Oral
Start date
Unknown
End date
Ongoing

Complete list of drugs taken by the patient

Antiretroviral treatment
Dolutegravir/Abacavir/Lamivudine
Complete list of all comedications taken by the patient, included that involved in the DDI

Zinc, cimicifuga, echinacea, licorice, giner, perilla, vitD3

Clinical case description

Gender
Female
Age
51
eGFR (mL/min)
>60
Liver function impairment
No
Description

Patient taking Triumeq plus different alternative medicines including zinc suplements. Potential interaction between zinc and Triumeq. It was recommended to take the supplements and the rest of complementary treatments separately 12h from Triumeq.

Clinical Outcome

No unwanted outcome

Editorial Comment

Coadministration may decrease dolutegravir concentrations due to complex binding to polyvalent ions (chelation). It is recommended to administer dolutegravir 2 hours before or 6 hours after taking the supplements containing polyvalent cations. Although the magnitude of the decrease in doluteravir concentrations may be ameliorated by taking dolutegravir and supplements together with food, there no data on zinc supplements specifically.

University of Liverpool Recommendation

Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
For more information click here